Enterprise Value

-125.3M

Cash

491.8M

Avg Qtr Burn

-40.33M

Short % of Float

9.59%

Insider Ownership

11.84%

Institutional Own.

84.63%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Update

Phase 2b

Update

Phase 1

Data readout

Phase 1

Data readout

CLN-049 (FLT3xCD3) Details
Relapsed/refractory acute myeloid leukemia, Acute myeloid leukemia

Phase 1

Update

CLN-978 (CD19xCD3) Details
Non-Hodgkin lymphoma, Blood cancer, Cancer

Phase 1

Update

Phase 1

Initiation